ALK and non-small cell lung carcinoma: The clinical advantages of Alectinib led to its approval by the U.S. Food and Drug Administration (FDA) for metastatic ALK-positive NSCLC in 2015, with an expanded indication for adjuvant therapy in 2024 [9,10].